DelveInsight Blogs Sitemap

All Posts in this category
S.No. Product Name Actions
1 Boston Scientific pays $336M; Boehringer Ingelheim acquires Abexxa Biologics; Oncology, RNA biotech 858 Therapeutics inks $60M Series A; Novartis acquires Arctos Medical Visit Post
2 Healthcare Data Breach: What it Means for Companies and the Consumer? Visit Post
3 Onychomycosis Therapy Market Set to Balloon Up as Emerging Novel Therapies Continue to Adorn the Space Visit Post
4 How Healthcare Apps are Adding New Perspectives to the Healthcare Industry? Visit Post
5 Iron Deficiency Anemia Market Growth Anticipated to Fuel at a CAGR of 3.7% by 2030 Visit Post
6 Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer Visit Post
7 Roche inks $3B deal; Owlstone raises $58M; FDA approves OCS heart system; Google, Mayo Clinic build brain-mapping AI algorithm Visit Post
8 Systemic Lupus Erythematosus Treatment Market: How the Leading Companies are Countering the Rising Prevalence? Visit Post
9 Reliable Experts in Pharmacology Market: Pharma Consultants Visit Post
10 Pfizer’s RSV Vaccine; Forte Biosciences’ Atopic Dermatitis Asset; Bone Therapeutics’ Osteoarthritis Programme; JandJ's HIV Vaccine Trial; Versanis Bio $70 M Series A Financing; AC Immune's Alzheimer's Antibody Drug Visit Post
11 Which Pipeline Therapy is Expected to Capture the Eyeballs in the Phenylketonuria Market? Visit Post
12 Charcot-Marie-Tooth Disease Market Size Expects Growth Owing to Increasing Prevalence, Influx of Pharma Companies and Novel Therapies Visit Post
13 Analyzing the Prospects of Drones in Healthcare Delivery System Visit Post
14 Ascendis's SKYTROFA; MicroTransponder’s VNS System (Vivistim); BioMarin's Voxzogo; Zimmer-Canary's Smart Knee Implant; COVID-19 impact on Solid Organ Transplants Visit Post
15 Venous Thromboembolism Market Growth Quadrant to Balloon Up Visit Post
16 Duchenne Muscular Dystrophy Market: What's More Beyond Exon-Skipping Therapies? Visit Post
17 Top 7 Pharma Industry Leaders in 2020 By the Numbers Visit Post
18 AstraZeneca's Ultomiris; HebaBiz's Siroquine; Pfizer's XELJANZ; Bristol Myers Squibb's Opdivo; and Masimo's PVi Visit Post
19 Von Hippel-Lindau Market Space Expected to Expand at a CAGR 8.3% by 2030 Owing to Increasing Prevalence and Emerging Therapies Visit Post
20 Fecal Incontinence Therapeutics Market Surges with Innovative Therapies in the Pipeline Visit Post
21 New Approaches and Evolutions to Reshape the Diabetes Management and Care Visit Post
22 FDA approval to Keytruda and Lenvima; FibroGen's Roxadustat; Pfizer’s TICOVAC; Ipsen’s Palovarotene; Jazz Pharma’s Xywav; Seagen-RemeGen’s Cancer Medicine Visit Post
23 Major Depressive Disorder Market Quadrant Growth Soars Owing to Expected Launch of Key Therapies Visit Post
24 Reimagining Clinical Trials: Why are Virtual Clinical Trials Becoming the New Normal? Visit Post
25 LQTT secures $19M; Nanox acquires Zebra Medical Vision; Takeda leads IBD drug; Visus raises $20M Visit Post
26 Merck’s Keytruda Approval; Abbvie’s Venetoclax; Aprea's Eprenetapopt; CRL to Incyte’s Retifanlimab; Keytruda/Lenvima for Endometrial Cancer Visit Post
27 Primary Hyperoxaluria Market Size Observes Growth with a Substantial CAGR Visit Post
28 Evolving Landscape for Rare Biomarkers in Non-Small Cell Lung Cancer Visit Post
29 Sanofi bets $3.2B on mRNA; Marinus signs $30M deal with Orion; Mestag with $45M seed; Moderna secures fast track designation Visit Post
30 Mounting Prevalence of Neurological Disorders and the Key Companies Bidding to Solve the Riddle Visit Post
31 Novel Therapies form the Nucleus of the Growth in the Crohn's Disease Therapeutic Market Visit Post
32 Amgen acquires Teneobio for $2.5B; Signifier scores $35M; Biogen-Ionis’ drug meets a goal; AbbVie hits go on $1B re-upped Calico deal Visit Post
33 Commencement of AAIC; GSK’s Shingles Vaccine Expanded Approval; Pfizer/ BioNtech Agreement with Biovac; Another Failure in Ulcerative Colitis Trial Visit Post
34 Fight Against the Antibiotic Resistance in the Uncomplicated Urinary Tract Infections Market Visit Post
35 Angelman syndrome Pipeline: Unmet needs call for a robust pipeline Visit Post
36 BlueRock secures FDA fast track; Omniscient rakes in $29M; Neuspera’s nerve implant gets a $65M boost Rivus’ therapy nabs $35M Visit Post
37 Leading Autoimmune Diseases to Undergo Robust Improvement in Treatment by Major Pharma Companies Visit Post
38 Hepion aces mid-stage study; Bicycle Therapeutics-Ionis collaboration; Nimbus raises $105M; Regeneron to support ISA Pharma Visit Post
39 Key Pharma Companies Expanding their Arm in the Skin Cancer Segment Visit Post
40 Bayer's CKD Drug; Enochian’s RNA Hijack for HBV; Novo Nordisk's to get Prothena's ATTR Amyloidosis Business; J&J’s COVID-19 Vaccine Struggle Visit Post
41 Unity's advanced vascular eye disease trial; Rallybio raises $100 M; Sanofi bets over $1B for Eureka's candidate; Lilly invests in MiNA; Visit Post
42 Charting out the COVID-19 Vaccine Landscape Visit Post
43 Arrowhead's ARO-ENaC Clinical Trial; Sartorius Acquires Stake in CellGenix; AGC Biologics's Cell & Gene Therapy; Sirnaomics Secures $105 Million Visit Post
44 Intellia's Quest with CRISPR; Innovent, Synaffix ADC Tech Deal; Lilly's Diabetes Blockbuster Tirzepatide; Polyphor’s Bleak Future Visit Post
45 Diabetic Macular Edema Therapy Market to Witness Significant Impact in the Foreseeable Future Visit Post
46 Insilico Medicine raises $255M; Sanofi & Translate Bio initiate trial; Medtronic gains expanded FDA approval; Blackstone, Cellex & Intellia form CAR-T startup Visit Post
47 Does the use of Assistive Technologies in Autism Spectrum Disorder Payoff? Visit Post
48 Horizon/ Arrowhead Deal; Dr Reddy's Lab’s Drug US Launch; Targovax’s ONCOS-102; RedHill's Oral Opaganib in COVID-19 Visit Post
49 How will Pharmacotherapies help the growing number of Presbyopes? Visit Post
50 Mallinckrodt earns FDA nod for skin therapy; RayzeBio secures $108M; VectorY raises $38M; Umoja banks $210M Visit Post
51 How Pharmaceutical Companies Are Mitigating The Gap In The Eye Disorders Treatment Market Visit Post
52 Eclipse, Medtronic, Aethlon, Cognoa, ObvioHealth, and others Continue to Veer MedTech Market Forward Visit Post
53 Aelis Farma pockets $30M; Alcyone unveils $23M for AAV gene therapies; Progentec and GSK collaborate; Kozin bags $60M Visit Post
54 Migraine Market: How Pharma Companies are trying to Uncomplicate the Disease and Bring in Novel Therapies Visit Post
55 Biogen’s Alzheimer’s Drug; FDA approval to Novo Nordisk’s Wegovy; Bluebird's Gene Therapy Visit Post
56 Continuous R&D Ramps Up the Pacemakers Pipeline Landscape, New Devices To Enter the Market Soon Visit Post
57 What factors are guiding the Growth of Endoscopy Fluid Management Systems in the MedTech Market? Visit Post
58 Latest Medtech Commercial, Regulatory and Clinical Updates For - Abbott, BD, CooperVision, Procyrion, TricValve, and others Visit Post
59 Diagnosis Delays, Ineffective Treatment Options Plaque the Bone Cancer Market Growth Visit Post
60 Amgen a leader in Undruggable Lung Cancer; Verrica's Skin Disease Drug Delays; Fennec's Faith in its Chemotherapy-Induced Hearing Loss Drug; Nexturn Bio's Acquisition of RosVivo Visit Post
61 Essential Demands Impinge the Evolving Adult-onset Still’s Disease Treatment Market Visit Post
62 Which Companies are Vying to get a Major Chunk in the Elastomeric Pump Market? Visit Post
63 Pieris-Genentech deal; Xilio inks deal with Merck; BMS taps Xencor's tech; GenSight's gene therapy reports partial recovery Visit Post
64 Alarming Growth of Chronic Respiratory Diseases (CRDs) and Their Prolonged Impact on the Quality of Life Visit Post
65 TLX66 in AL Amyloidosis; Takeda’s Dengue Shot; Innovent’s Cholangiocarcinoma Clinical Trial; Another Failed NASH Drug Visit Post
66 Is Antibody-mediated Rejection a Roadblock to Organ Transplantation? Visit Post
67 Who is Going to be a Trendsetter in the Hereditary Deafness Market? Visit Post
68 MedTech Industry: Commercial, Regulatory and Clinical Updates Visit Post
69 The Rising Burden of Substance Use Disorder And The Treatment Scenario Visit Post
70 InnoCare's Trial In China; Sanofi/GSK COVID-19 Vaccine; Apellis’s Empaveli for PNH; LianBio, Landos Collab Visit Post
71 Renal Tubular Acidosis Therapy Market and Sub-Optimally Effective Standard of Care Visit Post
72 Global Chronic Pain Associated With Painful Diabetic Neuropathy Market Landscape Visit Post
73 Lilly ink deal with MiNA; Appia Bio aims for CAR-T with $52M raise; Nuvalent raises $135M; Orchard gene therapy benefits kids Visit Post
74 Asthma: Rising Prevalence And The Key Challenges In The Management Visit Post
75 Abingworth & Alebund's Finacial Closing; Pfizer/BioNTech COVID-19 Vaccine Expanded Use; Biogen and Capsigen Deal Visit Post
76 Rising Awareness, Key Companies, Emerging Therapies? What is Shaping the Alagille Syndrome Market Visit Post
77 Market Heats Up as Managing Benign Prostatic Hyperplasia Through Devices Gains Traction Visit Post
78 Pfizer hit by DMD delay & halts BCMA trials; Sarepta's drug shows promise in Phase II; Human organ chips enable COVID-19 drug repurposing; AbCellera takes new antibody into clinic Visit Post
79 How Is Osteoporosis Impacting The Quality Of Life? Visit Post
80 MedTech Industry Roars Back as FDA Approvals Soar Visit Post
81 Can We Overlook The Potential Dangers That Come With AI In Healthcare? Visit Post
82 Glioblastoma Multiforme: Advancements in the Treatment Paradigm of the Malignant Condition Visit Post
83 Arch Oncology scores $105M; Abbott’s new coronary imaging platform; Lilly scraps IL-23 psoriasis program; Biogen offer access to experimental ALS med Visit Post
84 Understanding The Increasing Prevalence Of Diabetes And Its Complications Visit Post
85 Ocugen-Bharat Biotech’s Covaxin Against B.1.617 Corona Variant; uniQure Shares; J&J Covid Vaccine; Sanofi-Moderna COVID Vaccine Deal Visit Post
86 Sinusitis: Something More Troublesome Than Just Cold Visit Post
87 Pharma Companies Foray into the ABSSSI Market to Develop Novel Antibiotics and Tackle Antibiotic Resistance Visit Post
88 Vertex leads in CRISPR Therapeutics deal; Update for Phase 2 clinical trial of KVD824; Ovid dumps lead program; Virta Health pulls in $133M Visit Post
89 Which Pharma Companies are Working to Mitigate the Burden of Digestive Disorders? Visit Post
90 Adagio Raises $336 M; Lyndra's Schizo Trial; BMS Opdivo for Gastric Cancer; Anixa Ovarian Cancer CAR-T Therapy Visit Post
91 Drug Development and Pipeline Analysis in the Alzheimer’s Disease Market Space Visit Post
92 Ewing Sarcoma: Key Companies and Emerging Therapies in the Landscape Visit Post
93 Lilly’s Retevmo shows promise; CeQur tanks up on $110M in funding; Repertoire secures $189M; Recursion sets terms for $306M IPO Visit Post
94 Sleep Disorders: An Emerging Public Health Issue Visit Post
95 Taysha Acquires Rare Disease Gene Therapy For $5.5 M; AZ’s Farxiga Fails In COVID-19 Study; Sanofi To Strengthen Its Vaccines Manufacturing Capacities Visit Post
96 Alpha-1 Antitrypsin Deficiency: Symptoms, Treatments and Key Companies in the Market Visit Post
97 Limited Therapeutics Options and A Weak Pipeline: What Lies Ahead in the Cancer Anorexia Market? Visit Post
98 Artios collaborates with Novartis; Scholar Rock eyes Phase III trial; Novavax starts crossover arms in Covid-19 trials; Volastra nabs $44M Visit Post
99 E-Pharmacies: A Disruptive Innovation and the Future of Pharma Sector Visit Post
100 Cidara Therapeutics and J&J’s USD 780M Deal; FDA’s Approval to Supernus’s ADHD drug; Rain Therapeutics USD 100M IPO; NMPA Approval to Antengene’s ATG-019 IND Application Visit Post
101 Kinase Inhibitors: Challenging the established Biologics as the new standard of care in autoimmune diseases? Visit Post
102 A New Addition to Existing Chimeric Antigen Receptor Therapies –Potential for a Game Changer in Blood Cancers Visit Post
103 Amgen to acquire Rodeo for $55M; Novartis expands radioligand portfolio; Organon acquires Alydia for $240M; Forma announces positive FT-4202 dose levels Visit Post
104 How Depression Is Eroding The Mental And The Physical Health Of The Society? Visit Post
105 Bright Peak, Ajinomoto to Create Novel Immunocytokines; FDA’s Rejection to Lilly/Pfizer's Tanezumab for Osteoarthritis Pain; Ikena Oncology Unveils IPO Pricing Visit Post
106 Ever-Evolving Market Landscape of Transcatheter Aortic Valve Replacement Visit Post
107 How Will New Discoveries of Deep Brain Stimulation Devices Transform the Pharma Domain? Visit Post
108 Asher Bio raises $55M; Roche halts Huntington's phase 3 trial; Novartis' radioligand hits goal in phase 3; EpimAb raises $120M in Series C Visit Post
109 How Fitness Trackers Are Shaping the Future of Healthcare? Visit Post
110 Evotec, Takeda Deal; AZ COVID Vaccine US Trials; Promega’s Recognition; Roche's Tecentriq Results in NSCLC Visit Post
111 Which Pharma Companies are Transforming the Drug-Resistant Epilepsy Market Landscape? Visit Post
112 Navigating Through the Treatment Market Landscape of Head and Neck Cancers Visit Post
113 GBT strikes a deal with Sanofi; Lilly's IL-23 inhibitor shows promise; Glooko raises $30M; FDA uplifts hold on Solid’s DMD gene therapy Visit Post
114 Bleeding Disorders: How Key Companies Are Shaping The Bleeding Disorders Therapeutics Market? Visit Post
115 Merck, Gilead teams up for HIV treatment; Bright Future for Sanofi/Regeneron’s Libtayo; Roche acquires GenMark; FDA okays Melinta's Kimyrsa Visit Post
116 Hemophilia B Market: How Pipeline Therapies are Transforming the Treatment Hemisphere? Visit Post
117 Emerging Therapies in the Chronic Pain Pipeline Transforming the Chronic Pain Market Landscape Visit Post
118 Valo Health receives $110M Series B Cognito's therapy slows Alzheimer's disease Ventyx Biosciences raises $114M Takeda expands immuno-oncology portfolio Visit Post
119 Diagnosing At-Home: Are At-Home Diagnostic Tools The New Trends? Visit Post
120 Overwhelming success of Gilead/Kite's Yescarta; Ridgeback/ Merck in the COVID-19 game; AnaptysBio's antibody-drug failure; Roche discards Tecentriq for bladder cancer Visit Post
121 A Royal Disease: Hemophilia Visit Post
122 Rare Cancer Market: A Global Crusade on what is a ‘less common cancer’? Visit Post
123 Novavax targets COVID-19 approval; Iktos collaborates with Pfizer; AbbVie bags option to acquire Mitokinin; Presage inks new pact with Merck Visit Post
124 Applications of AI in Healthcare: COVID-19 and Beyond Visit Post
125 Evotec, Chinook Teams Up for CKD Therapy; HitGen & UPPTHERA in Drug Delivery Research; Artiva's $120 M Coup of NK Cell Therapy; Junshi & AZ with Toripalimab in China Visit Post
126 What are the Market Drivers Fueling the Rare Disease Market? Visit Post
127 Gene and Cell Therapies in CNS Disorders: Miracle Cure? Opportunities Galore! Visit Post
128 Beam makes USD 120M bet; GRAIL and Quest announce the collaboration; Brain organoids mimic infant’s brains; Improvement in T cells to kill cancer Visit Post
129 How Robots Are Introducing A New Dimension To Healthcare Service Delivery Visit Post
130 Clover biopharmaceuticals raises $230 M; BrainStorm after ALS; BARDA grants $5.65 M LightDeck for SARS-CoV-2 antigen test; Libtayo for first-line advanced NSCLC subset Visit Post
131 Emerging Research Continues To Transform Erythropoietic Protoporphyria Market Outlook Visit Post
132 Hypofibrinogenemia Market: Limited Pipeline Therapies, Abundant Opportunities Visit Post
133 Bluebird suspends gene therapy trials; Cortexyme tripped up by FDA hold; Guardant Health launches surveillance blood test; Enhertu scores approval Visit Post
134 Healthcare in 2021: Top Disruptions Bound To Impact The Way Healthcare Is Delivered Visit Post
135 Merck, Eisai in renal cancer market; G1 Therapeutics on Cosela’s approval; Takeda's Maribavir; Astellas/Seagen Padcev Visit Post
136 The Paradox of Rare: Chalking out Challenges in the Rare Disease Market Visit Post
137 Limited Therapies in the Rare Disease Pipeline: Watch out for Rare Indications that Calls Out for Novel Therapies Visit Post
138 Verily - Janssen collaboration; Enhancing the response in pancreatic cancer; Avrobio gene therapy eradicates toxic substrate; Gut microbiome responsible for Multiple Sclerosis Visit Post
139 Progeria: The Rarest Case of Premature Ageing Visit Post
140 Deerfield/ Dana-Farber’s USD 130 Million Cancer Research Deal; FDA-Approval to BMS’ Breyanzi & TG Therapeutics’ Ukoniq; EU Marketing Rights for ViiV Healthcare’s Rukobia Visit Post
141 Cystic Fibrosis Market: A Rapidly Expanding Playing Field for Mid-Cap Pharma Visit Post
142 The Mesh of the Generics and the Potential of Emerging Therapies in the Smoking Cessation Market Visit Post
143 Plaque psoriasis drug outshines in phase III trial; Immunovant announces pause in trial of IMVT-1401; Prothena brings AL amyloidosis drug back; Canon Medical expands its MRI AI programs Visit Post
144 Why Empathy Is More Important Today In Corporate Culture Than Ever? Visit Post
145 Fake News In The Healthcare Sector: A Misinformation Crisis In The Era Of Digitalization Visit Post
146 Horizon, Viela Deal; Concert Schizo Drug Flop; Gilead Deals with Arcus and Gritstone Visit Post
147 Chronic Refractory Cough Market and the Monopoly of the Over-The-Counter Drugs Visit Post
148 Notorious Hyperkalemia: What are the causes, signs and new treatments? Visit Post
149 Nirogy rises with $16.5M; Iterum presents a new drug application to FDA; Gut Bacteria proffer insight into molecules protection; TScan adds another $100M for cancer trials Visit Post
150 Eating Disorders: What Happens When Stigma And Misconceptions Command The Health Visit Post
151 Aurinia's Lupkynis for Lupus; FDA Fast Track Designation for Toripalimab; Wren Therapeutics’ Financing; Merck’s Covid-19 Vaccine Program End Visit Post
152 A Bleak Pipeline and Lack of Approved Treatment Clouds the Hemophagocytic Lymphohistiocytosis Market Size Growth Visit Post
153 Thrombocytopenia Drugs Market: What Newer Agents Are Expected To Enter The Market? Visit Post
154 Unshackling TP53 in leukaemia with a novel combo; Merus receives funds for cancer research pact; Vera Therapeutics bags $80M; Gritstone appends COVID-19 to the pipeline. Visit Post
155 We’re all in this together! Visit Post
156 The Burden And The Impact Of Mental Health Issues In Today’s Time Visit Post
157 Biohaven's Troriluzole Failure; Daiichi/ AZ's Enhertu; Fujifilm & Manufacturing Spree; J&J's Darzalex Faspro Visit Post
158 Angelman Syndrome Market: Insights Into The Recent Late-Stage Drug Failures And Novel Approaches To Treating This Rare Neurogenetic Disorder Visit Post
159 A Need for Curative Treatment Expected to Attract the Pharma Players in the Hallux Valgus Market Landscape Visit Post
160 Gilead and Vir collaborate; Tessera scores $230M; Teladoc & Dexcom bring CGM Tech; Verve unveils lead candidate Visit Post
161 The Obesity Pandemic: What can we do about it? Visit Post
162 Birinapant licensing; AvantGen, IGM pairs up for anti-SARS-CoV-2 antibodies; BeiGene, Novartis to co-dvelop Tislelizumab; Valo raises USD190 M; Bluebird Bio Spins-off Visit Post
163 Parkinson's Disease: How close are we to a cure? Visit Post
164 Increasing Prevalence and Upcoming Novel Therapeutic Approaches: What is Shaping the Hepatitis D Market Outlook? Visit Post
165 Ikena bags $120M; Terns raises $87M for NASH; Ribometrix Genentech Collaboration; Hologic acquires Biotheranostics Visit Post
166 Medical Tourism: Road to Affordable and Quality Medical Care Visit Post
167 Pfizer/ OPKO Health’s Somatrogon; FDA EU for SCONE device; Antengene ATG-010 for rrMM and rrDLBCL; SanBio STEMTRA Phase 2 Interim Results Visit Post
168 Search for the Cure Continues in the Chronic Hepatitis B Treatment Market Visit Post
169 Unmet Needs and Emerging Trends in the Acute Respiratory Distress Syndrome Market Landscape Visit Post
170 Improving cancer immunotherapy; Senseonics' Eversense delayed; FDA acknowledges Alkermes' Resubmission; 3D breast ultrasound improves diagnosis Visit Post
171 Alcohol Use Disorder (AUD): When Drinking Becomes A Headache Visit Post
172 A USD 4.2 Billion Myovant/ Pfizer Deal; Audentes Therapeutics’ ASPIRO Trial Free to Proceed; First Generic of Drug for Severe Hypoglycemia Gets Approval; Teleflex Acquires Z-Medica Visit Post
173 Watch Out For Top Pipeline Therapies Making An Impact In The Bipolar Depression Market Visit Post
174 Top 10 Most Promising Drugs In The Amyotrophic Lateral Sclerosis Treatment Landscape Visit Post
175 NIH awards $107M for COVID-19 testing tech; GSK secures rights; Roche's bispecific matches Eylea; Research Updates in Leukemia, solid tumors Visit Post
176 8 Of The Most Common Foods Allergies - Do You Have One? Visit Post
177 Agios' cancer pipeline auction; uniQure’s gene therapy on hold; Ultragenyx, Mereo Deal; aTyr Pharma Trial Visit Post
178 13 of the most commonly asked questions about Glioblastoma multiforme, Answered Visit Post
179 21 of the most common questions about Epilepsy Visit Post
180 Mitochondria destruction for Cancer Treatment; Atsena raises USD 55 Million financings; Novartis and Cadent Therapeutics collaboration; Neuron23’s strategy to tackle CNS disorders Visit Post
181 A Globally Rising Burden of Sexually Transmitted Diseases (STDs) Visit Post
182 FTA for Gannex’s ASC4; Disappointment for Incyte’s Ruxolitinib; Historic win for Pfizer, BioNTech’s COVID Vaccine; Alexion buyout; the debut of InnoSkel Visit Post
183 Evolution in Hepatitis B and C Virus: Can we expect success similar to Hepatitis C in Hepatitis B as well? Visit Post
184 Treating Patients with Software: Digital Therapeutics Visit Post
185 AstraZeneca’s COVID-19 vaccine; Type 1 diabetes research updates; FDA nod to Zebra's X-ray modelling AI; UniQure/CSL haemophilia B gene therapy curbs bleeding in phase 3 Visit Post
186 Will Wearable Devices be Streamlined in Healthcare? Visit Post
187 KaliVir, Astellas licensing deal; AbCellera's IPO; Bayer CAR-T Cell therapy collab with Atara; Aligos, Merck together against NASH Visit Post
188 Creating Future of MedTech Industry with Artificial Intelligence Visit Post
189 Advancements in Neuromodulation Visit Post
190 Roche's quantitative COVID-19 antibody test; Janssen buys a gene therapy asset; Zimmer Acquires A&E Medical; Glaucoma research study: Merck chooses TriNKET cancer immunotherapy program; Ovid fails Angelman phase 3 study Visit Post
191 Rheumatoid Arthritis: Causes, Risk Factors, Treatment Approaches and Market Landscape Visit Post
192 BASE10 Collaboration; Advaxis Public offerings; Takeda's CABOMETYX Japan approval; TheraPharm Acquisition Visit Post
193 Top Emerging Therapies To Watch Out for in the Retinal Vein Occlusion Market Visit Post
194 What are the options available for the treatment of Retinal vein occlusion? Visit Post
195 Cancer-killing virus flees immune destruction and attacks metastatic lung tumors; Urovant's vibegron fails trial; Genmab discards antibody-drug conjugate; Polyphor picks up $3.3M for inhaled antibiotic Visit Post
196 Bioterrorism: A Threat To The Healthcare And Global Peace Visit Post
197 Novartis' COVID-19 deal; Shattered hopes for Remdesivir; Lilly's R&D pact with Precision; Innovent's Humira Biosimilar Visit Post
198 Fierce Competition Lies Ahead for Pipeline Therapies in the Rheumatoid Arthritis Market Visit Post
199 Biliary Tract Cancer: Emerging Players in the Market Transforming the Treatment Landscape Visit Post
200 Pfizer succeeds COVID-19 vaccine safety milestone; Sanofi snags speedy review for BTK drug; Autoimmune diseases research updates; Elevation Oncology secures $65 M Visit Post
201 Lung Cancer and its Increasing Global Burden Visit Post
202 Albireo Pharma's PFIC Therapy; Lupin’s Trichomoniasis Oral Drug; Moderna's Weapon Against COVID; Gilead & Novo Nordisk's Cocktail Therapy for NASH Visit Post
203 Ever-evolving Market Dynamics of Epilepsy – a silver lining! Visit Post
204 The Present Rheumatoid Arthritis Treatment Market Offers a Mix-and-Match Approach Visit Post
205 FDA authorizes first diagnostic test for Covid-19 antibodies; EGenesis's collaboration with Duke; Pancreatic Cancer research updates; Decibel scores $ 82 M Visit Post
206 Is Subscription Model Going to be the New Normal for Healthcare Industry? Visit Post
207 Pfizer's COVID-19 Vaccine; Calliditas' NefIgArd trial; ViiV's HIV Prevention Treatment; Biogen’s Aducanumab Rejection Visit Post
208 Key Pharma Players Transforming the Complement 3 Glomerulopathy Market Landscape Visit Post
209 Argininosuccinic Aciduria Market Awaits Innovative Treatment Expected To Launch In The Next Decade Visit Post
210 Fosun-BioNTech's COVID-19 vaccine; Multiple Sclerosis research update; Vosoritide nabs FDA review; FDA nods to paclitaxel-coated Ranger balloon for PAD Visit Post
211 Bristol Myers' psoriasis drug; GW Pharmaceuticals eyes US market for Nabiximols; Karyopharm's Xpovio; Kiadis USD 358M Buyout Visit Post
212 Trump vs. Biden: What is in Store for Healthcare Domain? Visit Post
213 Pharma Players Line Up To Launch Novel Therapies Fueling Epidermolysis Bullosa Market Size Visit Post
214 Which pipeline therapy has the potential to revolutionize the Down Syndrome Market? Visit Post
215 Novartis taps Molecular Partners to combat COVID-19; GSK culls phase 2 asthma drug; Exact Sciences acquires Thrive for $ 2.15 B; EQRx-CStone's deal for checkpoint inhibitors Visit Post
216 How Will Artificial Intelligence Change The Future Of Healthcare? Visit Post
217 Bayer eyes AskBio’s Gene Therapies; Novartis' Iptacopan; Forma's IDH1-Mutated AML Therapy; EpicGenetics teams up with Mayo Clinic Visit Post
218 7 Most Common Myths About Breast Cancer Demystified Visit Post
219 Key Facts To Know About Triple-Negative Breast Cancer In The Breast Cancer Awareness Month Visit Post
220 GSK's RSV vaccine; SparingVision's interest in gene therapy; InCarda's raise; BridgeBio's R&D deal Visit Post
221 Adding Value to the Health with a Value-Based Healthcare Model Visit Post
222 Venclexta full approval; PBP1510 Orphan Status; Roche/ Genesis collab; Immunomodulators for COVID-19 Visit Post
223 The Growing Burden Of Neurodegenerative Disorders Visit Post
224 Breast Cancer: Understand your breasts, recognize the symptoms Visit Post
225 Cyclerion's olinciguat flunks sickle cell test; Nimbus nets $60M; Dyno-Roche's gene therapy pact; RayzeBio debuts with $ 45M to target tumors Visit Post
226 Understanding The Disparities In The Healthcare Sector Visit Post
227 US/AZ deal; Alkermes' Schizophrenia drug; Innovent/Lilly's China market expansion; Rejection for Avenue Visit Post
228 Market Drivers and Barriers That Will Shape The NMIBC Market In The Next Ten Years Visit Post
229 Key Pharma Players Changing The Dynamics Of Schizophrenia Market Visit Post
230 Santhera flunks DMD phase 3; Scribe emerges with $20 M; Merck sells off Osteoarthritis drug to Novartis; Research updates on flu vaccine and glioblastoma Visit Post
231 How do we curb the Opioid Epidemic? Visit Post
232 MyoKardia buyout; Eidos acquisition; Amgen's Aimovig; HCV discovery; Bharat Biotech's Covaxin Visit Post
233 Key Companies To Keep an Eye on for Pipeline Therapies in Osteosarcoma Market in the Next Decade Visit Post
234 Pitfalls of Current Osteosarcoma Treatment Approaches Visit Post
235 Brain's immune cells research update; Moderna's COVID-19 vaccine; Pfizer funnels $200 M into CStone; Myovant's relugolix falls short in metastatic prostate cancer; Alnylam's lumasiran phase 3 result Visit Post
236 Conditions Medical Marijuana is Anticipated to be Prescribed in the Offing Visit Post
237 Inovio's COVID vaccine trial On-hold; Appeal to Pfizer; XtalPi's massive raise; GSK Nucala's HES approval; J&J's COVID vaccine Visit Post
238 Glioblastoma Multiforme Market: Emerging Pipeline Therapies To Keep A Keen Eye On Visit Post
239 Huge Unmet Needs in the Glioblastoma Multiforme Treatment Market Driving the Market Size Growth Visit Post
240 J&J 's COVID-19 vaccine; Roche, AC Immune's anti-Tau Alzheimer's drug; Silverback nets $85 M; Anokion's deal rides out BMS-Celgene merger; Coronavirus spike protein could inspire vaccine development Visit Post
241 Samsung/AZ Deal; Gyroscope’s Dry AMD Gene Therapy; Inflazome's Buyout; Abbott’s MitraClip4 EU Approval; Grail Buybacks Visit Post
242 Roadblocks In The Peripheral Nerve Injury Market Require A Multi-faceted Approach Visit Post
243 Cervical Cancer Market Has A Lot Going On Under The Hood Visit Post
244 Lilly's COVID-19 antibody reduces hospitalization rate; Tiny biologic drug to combat COVID-19; Aziyo Biologics files for $57.5 M IPO; BMS exercises option on Obsidian's CD40L cell therapy Visit Post
245 While AZ resumes its COVID-19 vaccine trial in the UK; Merck and Gilead are busy making sizeable Breast cancer deals Visit Post
246 Preventing Cervical Cancer Through Screening And HPV Vaccines Visit Post
247 What Does The Acromegaly Pipeline Have Up In Its Sleeve? Visit Post
248 Pfizer-BioNTech COVID-19 vaccine trials; OncoImmune raises $56 M; Recursion Pharma nets $239 M; Breast cancer research updates Visit Post
249 The State of Alternative Medicine In The Healthcare Visit Post
250 Cycle Pharmaceuticals' USD 25M Debt Financing; Bayer’s Phase IV REPLACE Trial; Verona's Pilot Study with pMDI Ensifentrine in COVID Patients Visit Post
251 Multiple Myeloma: An Incurable B-cell malignancy and A Vicious Cycle of Relapse Visit Post
252 Keratoconus - Rare? Not really! Visit Post
253 Amylyx's neuron-protecting drug slows ALS decline; Antisense drugs could help fight ALS and dementia; CAR-T research updates; Orca and Lyell announces research partnership Visit Post
254 Healthcare Delivery System: What lies in the future? Visit Post
255 Nestle to acquire Aimmune Therapeutics; Vir Bio & GSK's COVID-19 monoclonal antibody therapy; AstraZeneca's Farxiga scores goal in Phase III CDK trial Visit Post
256 Do We Have A Cure For Rosacea? Visit Post
257 The Rarity Of Dravet Syndrome: Challenges, and Treatments Visit Post
258 Moderna's COVID-19 vaccine trial; Freenome secures $270 M; CRISPR treats obesity in mice; Breast cancer research updates Visit Post
259 Social Determinants of Health Goes Beyond Just Healthcare Visit Post
260 Novartis’s Spartalizumab Combo Stumbles; Union Therapeutics Doses In COVID-19 Trial; Yumanity To Merge With Proteostasis Visit Post
261 What Can Help Manage The Insufficient Pancreas? Visit Post
262 Interstitial Cystitis: A big opportunities for emerging drugs Visit Post
263 FDA rejects BioMarin's Valoctocogene Roxaparvovec; J&J inks $6.5B deal; Alzheon bags $47M; Research updates on diabetes Visit Post
264 Nutrition Intervention: Foods to take and foods to avoid when suffering from Gastroparesis Visit Post
265 Sanofi acquires Principia; FDA's Nod to Roche's Enspryng; BMS, Dragonfly's Licensing Deal Visit Post
266 New Hopes; New Horizons: Gastroparesis Market Has Mighty Treatment Options On Its Sleeves Visit Post
267 Celiac Disease: The Hidden Epidemic of Gluten Sensitivity Visit Post
268 Gilead's remdesivir trials; F2G raises $60.8M; Cancer immunotherapy research updates; Celleron gains rights to Roche's cancer drug Visit Post
269 Infectious Diseases That Possess Significant Challenge To Humans Health Visit Post
270 FDA's Ok to Roche's Oral SMA Therapy; Roche's Etrolizumab Mixed Results in Ulcerative Colitis; Secura receives rights to Copiktra from Verastem Visit Post
271 Boehringer Ingelheim; Roche demonstrated new analyses of their drugs in patients with ILDs during the American Thoracic Society (ATS) Virtual conference Visit Post
272 Merck; Bayer; Shionogi set to showcase their candidates indicated for Chronic RefractoryCough in the ATS Virtual Conference Visit Post
273 Medical Marijuana: Is it a blessing in disguise or a curse for humanity? Visit Post
274 Unfolding The Folds Of Transthyretin Visit Post
275 Zydus starts Phase II COVID-19 vaccine trial; Taysha raises $95M; FDA declines DBV's peanut allergy patch; Combating COVID-19 with decoy target Visit Post
276 Recognising The Warning Signs Of ADHD Visit Post
277 MorphoSys, Incyte receive FDA Ok for Monjuvi; Siemens Healthineers set to buy Varian; Immunic's IMU-838 promising results Visit Post
278 Enough Of Wasting Away From Cancer: Companies Gear Up To Tackle Cachexia Visit Post
279 A Complex Chromosomal Abberation Called Adrenoleukodystrophy Visit Post
280 Roche-UCB's $120M collaboration; Omega snags $85M; ExeVir raises $27M; GSK culls pipeline meds after failures Visit Post
281 In The Global Race For The COVID-19 Vaccine, India Stands As A Strong Player Visit Post
282 AZ, Daiichi inks an oncology deal; Moderna begins Phase III trial of its COVID-19 vaccine; No good news for Solid's DMD gene therapy trial Visit Post
283 Addressing The Scattered Harbingers of Frontotemporal Dementia Visit Post
284 Rejections and Withdrawals: Familial Chylomicronemia Syndrome Market Needs a Therapy Effective Enough, Affordable Enough Visit Post
285 Olema raises $54M; T3 Pharma bags $27M to advance bacterial cancer therapy program; Biofourmis and Chugai's Collaboration; A new study on averting heart attack Visit Post
286 AZ shows positive results for its COVID-19 vaccine; Synairgen offers a new approach to address COVID; GSK, CureVac forms mRNA strategic partnership Visit Post
287 Watch Out for the Most Promising Therapies in the Pipeline in Acute Kidney Injury Market Visit Post
288 An Eye-Blinding Scenario of Vernal keratoconjunctivitis Visit Post
289 Orchard licenses gene therapy tech from GSK; Glympse raises $46M; FDA voted to recommend Terlipressin; Breast Cancer research update Visit Post
290 What are the Top Five Leading Causes of Deaths in the World? Visit Post
291 Merck, Dewpoint's HIV Pipeline; Pfizer, BioNTech 's COVID-19 Vaccines; Roche’s Tecentriq- Avastin Duo Failure in Ovarian Cancer Visit Post
292 Metabolic Acidosis: Counting The Unmeasured Anions And Closing the Gap In Blood Serum Visit Post
293 Spot the Signs and Fight Postpartum Depressions Visit Post
294 Kiadis inks license deal with Sanofi; Gilead Ends Hep B Collaboration; Merck & Foghorn inks $425M deal; Tregs research updates Visit Post
295 The Most Promising COVID-19 Vaccine Candidates In The Pipeline To Watch Out For Visit Post
296 Regeneron's cocktail antibody, REGN-COV2; J&J's manufacturing-spree; ObsEva's Yselty top-line studies Visit Post
297 Rising Nontuberculous Mycobacterial Infection Prevalence Poses A Major Public Health Concern Visit Post
298 Small Cell Lung Cancer Market Booms with an Influx of Companies and Robust Pipeline Visit Post
299 Amylyx Raises $30M; QurAlis Announces License Agreement Deal With Lilly; COVID-19 Vaccine Updates; Researchers Develop a New Ultrafast Insulin Visit Post
300 Top 5 Cancers Creating Major Challenge To The Global Healthcare System Visit Post
301 FDA’s No to Intercept’s NASH Drug; Roche’s Phesgo gets approval; Gilead’s Remdesivir pricing Visit Post
302 In Search for a Curative Treatment Option for Duchenne Muscular Dystrophy Visit Post
303 The Increasing Global Burden of Cytomegalovirus Seroprevalence Visit Post
304 Regeneron's I-O Drug; Gene Therapy for Parkinson's Disease; Yumanity and Merck Inks $500M Deal; Simcha Raises $25M Visit Post
305 Can Alzheimer's be cured with Marijuana? Visit Post
306 Sarepta & Codiak Inks $72.5M Deal; Invitae to Acquires ArcherDX; Merck announces V114's Phase III result Visit Post
307 Mapping The Pipeline Development In The Geographic Atrophy Market Visit Post
308 Paradigm Shift In The Diabetic Peripheral Neuropathy Market Landscape As The Focus Shifts Towards The Cure Visit Post
309 Lassen’s anti-IL-11 antibody; PTC’s COVID-19 trial; Lenzilumab's result; Orca raises $192M Visit Post
310 The Question That Remains Unanswered: What Might Be Causing Alzheimer’s? Visit Post
311 HCQ/ CQ failure; AZ/ Catalent’s deal; Sinovac’s CoronaVac and Lilly’s Olumiant trial results Visit Post
312 How are Diabetic Peripheral Neuropathy medications changing the DPN market scenario? Visit Post
313 Can Aducanumab Slove the Puzzle Of Alzheimer’s? Visit Post
314 AbbVie & Genmab’s Collaboration; Lilly's antisense neuro deal; COVID-19 treatment updates; Roche’s partnership with Innovent; Visit Post
315 When Technological Innovations Help in Remembering for People Living with Alzheimer’s Visit Post
316 Alnylam’s lumasiran results; AZ’s oncology drug; Astellas Roxadustat; Evotec’s partnership with ABL Visit Post
317 With the Advances in Regenerative Therapy to Offer Curated Treatment Options, Off-label Therapy Market is Set to Decline for Dilated Cardiomyopathy Visit Post
318 Prostate Cancer Market Experiences an Influx of the Pharma Players Veering the Market Ahead Visit Post
319 Gene-edited T cells for diabetes treatment; Pliant raised $144 million; Accent, AstraZeneca aim RNA modifiers in cancer deal; NodThera Raises $55M; Visit Post
320 What are the 10 early signs of Alzheimer’s that are overlooked? Visit Post
321 Eli Lilly's COVID-19 Antibody trial; Approval for Oriahnn; Gilead's Remdesivir Clinical Trials result; Russia approves Avifavir to treat Covid-19 Visit Post
322 An Ageing Population and Upcoming Therapies: What is shaping the Alzheimer’s Disease Market Scenario? Visit Post
323 One of the leading causes of blindness, and a sight-threatening disease, Uveitis, now has novel treatment approaches in its pipeline Visit Post
324 Startup focuses tumors with CAR-T; AbCellera grabs USD 105M; Gilead inks USD 2B deal; GSK’s anti-BCMA antibody receives a boost Visit Post
325 Precision Medicine: An emerging approach to conventional treatment Visit Post
326 Algernon's NP-120; FDA nod to 4DMedical tool; SaNOtize's NORSTM trial; Pole's capital increase Visit Post
327 R&D and Upcoming therapies Paving the Way for a Potential and Better Cure for Immune Thrombocytopenia Visit Post
328 Hunter Syndrome Market experiences a positive push as the pharma companies spot the untapped opportunities Visit Post
329 CanSino deals with Precision; Atea raises USD 215 M; Applied Molecular Transport targets for USD 100 M IPO; Cell therapy repairs multiple sclerosis in mice Visit Post
330 Keeping a track on COVID-19 through Wearable Technology Visit Post
331 Moderna's COVID-19 Vaccine; Quidel's Lyra gets EUA from FDA; Neurotrope and Metuchen Pharma Announced Merger Agreement; FDA Approval to Rucaparib; Visit Post
332 Is the cure for Duchenne Muscular Dystrophy in the pipeline? Visit Post
333 Emerging Therapies that can significantly impact the Acute Kidney Injury Market Visit Post
334 Merck supports Peloton Therapeutics; Thermo Fisher, WuXi and Mayo Clinic join hands; JNJ's anti-BCMA CAR-T sweeps multiple myeloma aside; Tafinlar-Mekinist combo of Novartis receives a boost Visit Post
335 Security Breach: A Growing Concern For The Healthcare Industry Visit Post
336 Mavacamten Phase III clinical trial, FDA nod for Ovarian cancer therapy, Dyno Therapeutics & Novartis Collaboration, Abbott's COVID-19 diagnostic kit Visit Post
337 Is the cure for Huntington’s disease on the horizon? Visit Post
338 Overcoming the prevailing unmet needs in Beta-Thalassemia Market Visit Post
339 Avrobio taps Magenta’s ADC; Eli Lilly ramps up; FDA postpones decision; CSL gears up to fight pandemic, Visit Post
340 Will there be a second wave of coronavirus? Visit Post
341 Acquisition of Stemline; Roche’s Elecsys Anti-SARS-CoV-2 antibody test; Newron’s abandonment of STARS trial Visit Post
342 Altering the course of Ovarian cancer with emerging therapies in the horizon Visit Post
343 Novel mutation-targeting therapies in the horizon to relieve the global healthcare burden NSCLC poses Visit Post
344 Remdesivir accelerates for COVID-19 recovery; Merck pact with Almac; Pfizer, BioNTech finish dosing in; Taysha Gene Therapies for trials Visit Post
345 In the race to fight SARS-CoV-2: Merck, ISB; ViiV; Genalyte gears up Visit Post
346 Chemotherapy Induced Febrile Neutropenia Market: High time to end the monopoly Visit Post
347 Changing the Paradigm of Cancer: Neoantigen based Personalized Cancer Therapeutic Vaccines Visit Post
348 AbbVie, Sofinnova back; Gilead, Kite ink; Biogen aims filing; Reversing diabetes Visit Post
349 Potential Diagnostic solutions that may significantly contribute to COVID-19 detection Visit Post
350 COVID19 pipeline advances as Novartis begins phase III trial of hydroxychloroquine; and advancements in RCC, and HER2 positive breast cancer market Visit Post
351 Novel coronavirus crumbles down as soon as it lands on copper Visit Post
352 CAR-T cell therapy market for Non-Hodgkin lymphoma: Future prospects, and untapped opportunities Visit Post
353 Vir's drug shows results; Abbott launches coronavirus antibody lab test; Reprogrammed skin cells repair vision in mouse models; Moma Therapeutics focuses for molecular machines Visit Post
354 Supply shortage: Why ventilators are in demand amid the Coronavirus crisis Visit Post
355 In the fight against COVID-19 – Lilly with Olumiant, Gilead with remdesivir, Rutgers with testing kit Visit Post
356 Is Hydroxychloroquine the answer to all the COVID-19 questions? Visit Post
357 Future Perspectives Of CAR-T Cell Therapy Market In Acute Lymphoblastic Leukemia (ALL) Visit Post
358 AstraZeneca targets for COVID-19 antibody trial; Arrakis, Roche team up; GSK, AstraZeneca launch testing lab, U.S. government funds OraSure Visit Post
359 COVID-19 crisis can prove to be a catalyst for Artificial Intelligence in Healthcare Visit Post
360 Immunomedics Halts Sacituzumab govitecan trial; GSK-Vir Biotech collaboration; INO-4800 DNA COVID-19 Vaccine; Pfizer Commits $ 40M for COVID-19 Visit Post
361 World Health Day Visit Post
362 Warm Autoimmune Hemolytic Anemia: A less prevalent disease with prevailing unmet needs Visit Post
363 Warm Autoimmune Hemolytic Anemia Epidemiology forecast segmentation, treatment approaches, and WAIHA market forecast Visit Post
364 Niacin fights Glioblastoma, iTeos nets $125M, Pandion reels in $80M, Brii, Chinese partner, FDA to speed up COVID-19 therapies Visit Post
365 Telemedicine: Can it be the future of healthcare? Visit Post
366 J&J's COVID-19 Vaccine; GigaGen COVID-19 therapy; FDA approved Abbott's POC test; Cobra Bio raises $ 3.3 M Visit Post
367 Realm of Pandemics: Were we prepared then? Are we prepared now? Will we be ever prepared? Visit Post
368 What is driving Retinitis pigmentosa market forward? Visit Post
369 FDA permits COVID-19 treatment, Roche's antibiotics pact, Moderna's vaccine, FDA permits Remdesivir, ReCode needs USD 80 Million Visit Post
370 Thermo’s investment; Biohaven’s vazegepant Phase III trial; Cumberland’s aid Visit Post
371 Retinitis Pigmentosa: A complex disease, and the increasing gap between prevalence and diagnosed prevalence Visit Post
372 Soft Tissue Sarcoma Market size to increase with a CAGR of 6.47% – Emerging therapies and Increasing Incidence form major market drivers Visit Post
373 Sage seeks to save depression drug; Regeneron aims clinical trial; J&J sets sights for COVID-19 trial Visit Post
374 Should you wear contact lenses amid coronavirus outbreak? Visit Post
375 Moderna’s COVID-19 vaccine; AcelRx buys TetraPhase; Breakthrough designation to Baricitinib Visit Post
376 Dubai: A leading and exciting pharma hotspot Visit Post
377 Questions and Answers on the Novel Coronavirus Disease (COVID-19) Visit Post
378 JNJ-6372 nabs FDA nods, Solid tumors treatment, Kevzara for COVID-19 Visit Post
379 Ofev’s expanded use; Arkin Bio-Ventures II launch; USD 125 M for COVID-19 treatment Visit Post
380 Soft Tissue Sarcoma Treatment Market: Present treatment approaches and Unmet Needs Visit Post
381 Top healthcare innovations changing the healthcare dynamics Visit Post
382 Soft Tissue Sarcoma: A rare malignancy Visit Post
383 CAR-T in killing tumors; Amunix raises $73M; Autism findings in protein-targeted treatment Visit Post
384 Gene therapy might make cocaine less addictive Visit Post
385 Gilead to buy Forty Seven; Akrevia Therapeutics unveils new identity; FDA approved pyrimethamine Visit Post
386 Opioid Withdrawal Syndrome Pipeline: What lies in the future for those facing withdrawal symptoms Visit Post
387 US approval to Lundbeck’s Vyepti for preventive migraine care; Esperion’s cholesterol-lowering drug Nexletol receives FDA nod; Karius – a start-up company – raises USD 165 Million – strengthens it liquid biopsy testing Visit Post
388 Opioid Withdrawal Syndrome: What happens when a person withdraws from Opiates Visit Post
389 Booming Healthcare sector in MENA: Lucrative opportunity for Global pharma players Visit Post
390 Incyte meets endpoint in second atopic dermatitis trial; NeoTX lands USD 45 M series C; Five Prime Therapeutics’ pancreatic cancer a bust Visit Post
391 Cardiovascular Disease: A major cause of health loss and a global burden Visit Post
392 Why should every company working on CAR-T therapy attend CAR TCR Summit Europe? Visit Post
393 Promising therapies that might shift Wet Age-related Macular Degeneration Market in the next decade Visit Post
394 Wet Age-Related Macular Degeneration: Unravelling the complex disease with comprehensive R&D Visit Post
395 J&J collaborates with BARDA; Virus kills pancreatic cancer cells; ALX raises USD 105 million for CD47 drug Visit Post
396 The epidemic now has a name: COVID-19 Visit Post
397 Good news for Kite’s KTE-X19, and Aquestive’s Libervant; and a commercialization deal between ReForm Biologics, MilliporeSigma Visit Post
398 Bridging the gap: Nontuberculous mycobacterium Infections Drug Pipeline Visit Post
399 Immune cells for age-related diseases; Regeneron's antibody for 2019-nCoV; FDA nods for hydrogel injection Visit Post
400 Nontuberculous Mycobacteria Infection Market: Current status of NTM infection drug discovery and development Visit Post
401 First-ever Peanut allergy treatment; Dinutuximab misses primary endpoint; Insmed's shares Soares Visit Post
402 Lack of effective therapy: A major Nontuberculous Mycobacteria Infection Market Driver Visit Post
403 Wuhan Coronavirus: A global emergency Visit Post
404 Annovis announces IPO results; Conatus merges with Histogen; Novartis discontinues its generic journey Visit Post
405 Thyroid awareness month Visit Post
406 Acceleron Pharma's drug sotatercept touches the phase 2 mark; GT Medical receives nod for GammaTile; New treatment strategy for Parkinson's disease Visit Post
407 Introducing a new brand identity, and a new website: DelveInsight. Visit Post
408 Thyroid eye disease market: New therapies enter the TED market Visit Post
409 Tepezza receives approval; a new way to treat Alzheimer’s Visit Post
410 Polypills: Can they offer a potential approach to treat CVDs? Visit Post
411 Imfinzi combo gets ODD; Mayzent gets EU nod; Positive results of VP-102 Visit Post
412 In a blind race to cure HIV, can Gene therapy be a deal-breaker? Visit Post
413 Thumbs down to NKTR-181, Lilly expands its insulin armamentarium Visit Post
414 Malignant Pleural Mesothelioma Upcoming Therapies Visit Post
415 Eli Lilly to acquire Dermira, Boehringer buys Enleofen’s IL-11 platform, Biogen acquires Pfizer’s Alzheimer’s drug Visit Post
416 Malignant pleural mesothelioma market: Elusive treatment approaches and Poor diagnosis Visit Post
417 Anaphylaxis: A Rare Disease Visit Post
418 Novome raises USD 33M, Buyout of Bioniz, Adagene raises USD 69M Visit Post
419 Marijuana as a treatment approach Visit Post
420 Nunaps raises USD 4.2M; Arcutis files for USD 100M IPO Visit Post
421 Egg Allergy Market: Second most common food allergy but no approved therapy Visit Post
422 Chronic Hand Eczema Market Analysis and Forecast Visit Post
423 Angelman syndrome: A Rare Genetic Disorder Visit Post
424 Atopic dermatitis market and a Dupilumab dominance Visit Post
425 Atopic dermatitis market: Increasing prevalence and topical treatments Visit Post
426 Allergic rhinitis market: How common is Hay fever? Visit Post
427 Global Allergic disease market Visit Post
428 Roche, Sarepta collaborates; FDA approval for Merck’s Ervebo, and Allergan’s Ubrelvy Visit Post
429 Autologous cell therapy market: A new paradigm for kidney diseases Visit Post
430 Reversing Ischemia with Gene therapy Visit Post
431 GBT, Syros; Takeda, Cevance collaborates; IND application to ZN-c3 Visit Post
432 Schizophrenia vs Bipolar disorder: Biomarkers to the rescue Visit Post
433 Wave Life Sciences stocks implode; Amarin’s VASCEPA approval; GSK seeks approval Visit Post
434 Increasing cases of Mania and Bipolar disorder market Visit Post
435 Fragile X Syndrome Market Visit Post
436 Omega’s sixth funding round; Correvio’s drug failure; and BIMA acquisition Visit Post
437 Gaucher disease Market Analysis: Rich Pipeline Drives the Market Ahead Visit Post
438 Acquisition of ArQule; Synthorx; and Zentalis nabs a raise Visit Post
439 Are Rare Diseases truly Rare? Visit Post
440 Reblozyl under FDA review; Audentes buyout & Tecentriq’s new approval Visit Post
441 The Regulatory process for drug approval in the MENA region Visit Post
442 Cumberland’s methotrexate product gets approval in the US; Baker Brothers purchases stake in Kodiak’s KSI-301; Sanofi offloads Seprafilm unit to Baxter Visit Post
443 National Influenza Vaccination Week Visit Post
444 Chronic Refractory Cough Market landscape: A new approach to treating cough Visit Post
445 World AIDS Day- 2019 Visit Post
446 Alzheimer's Disease Market Infographic Visit Post
447 UREA CYCLE DISORDER - A LOST ENZYME may lead to FATAL RISKS Visit Post
448 Toujeo to treat Type 1 Diabetes; TauRx for Alzheimer’s patients Visit Post
449 Novel treatment approval promises a better future for Sickle cell disease patients Visit Post
450 Novartis buys Medicines Co. for USD 9.7 Billion Visit Post
451 How Gene therapy is changing the Beta-thalassemia Treatment outlook? Visit Post
452 The long journey of Biosimilars: Is it an emerging opportunity? Visit Post
453 GHO to advance healthcare in Europe; Truvian nets USD 27.1 Mn; Lilly plans its diabetes portfolio expansion Visit Post
454 Antimicrobial resistance crisis: A global need for antibiotic awareness Visit Post
455 World COPD Day Visit Post
456 Nordisk ties up with Dicerna; Pfizer's drug gets FDA nod Visit Post
457 Complex Regional Pain Syndrome Upcoming Therapies Visit Post
458 Is Air Pollution a driver in COPD Treatment Market? Visit Post
459 AbbVie Sells bonds to Fund Allergan takeover Visit Post
460 World Diabetes Day | 2019 Visit Post
461 Beta-Thalassemia Pharmacological Therapies Visit Post
462 FDA declines the approval of Lipocine’s testosterone drug; Novartis Sandoz to buy Aspen Pharmacare Japanese Unit Visit Post
463 Parkinson’s Disease Market: Impact of Emerging therapies on Parkinson’s therapeutics market Visit Post
464 Metastatic Pancreatic Cancer Market Size: Emerging therapies, Unmet needs and Forecast analysis Visit Post
465 Evotec, Vifor Pharma collaborates to cure kidney diseases; AZ takes major steps to advance pharma and medicine R&D in China; Amneal licenses-in a Myasthenia Gravis drug from Kashiv BioSciences Visit Post
466 Non-small cell lung cancer emerging therapies Visit Post
467 AstraZeneca tops the first Pharma Invention Index; Amgen to buy 20.5% stake in a Chinese pharmaceutical, BeiGene; Ascentage, Henlius collaborates to develop a Combination therapy Visit Post
468 The growing size of Sanfilippo syndrome Market: Drivers and Barriers Visit Post
469 Non-Small Cell Lung Cancer Market: Treatments and Market Forecast Visit Post
470 AZ sells EU rights for Schizophrenia to Cheplapharm; Astellas, Pandion unite to extract the potential of immunomodulation; Pear therapeutics on a journey to develop digital GI treatments with Ironwood Visit Post
471 Geographic Atrophy Treatment Market: Novel Therapies to Enter the Market Visit Post
472 World Psoriasis Day Visit Post
473 AZ announces positive results for durvalumab and tremelimumab; FDA nods to extend LILETTA’s use to prevent pregnancy; Gilead, Glympse Bio teams up to advance NASH clinical development Visit Post
474 Refractory Metastatic Melanoma Market Visit Post
475 Onychomycosis therapeutics market: Impact of new topical anti-fungal drugs Visit Post
476 Metastatic HER2-Positive Breast Cancer Infographic Visit Post
477 Rapt Therapeutics files IPO; Novartis stakes $80M for NASH Visit Post
478 Biogen seeks the FDA approval to revive its Alzheimer’s drug Aducanumab Visit Post
479 FDA approval to AZ’s Farxiga for heart failure; GSK divests two travel vaccines to Bavarian Nordic; New breakthrough therapy for Cystic Fibrosis Visit Post
480 Emerging drugs bring a positive shift in Global Osteoporosis Market Visit Post
481 World Osteoporosis Day Visit Post
482 Incyte Corporation submits positive results of trials for its drug Ruxolitinib in GvHD Visit Post
483 EicOsis receives USD 15M to fuel its non-opioid pain therapy; Alexion Pharmaceuticals buys Achillion Pharmaceuticals; Ipsen adds another drug to its rare disease pipeline Visit Post
484 New Therapeutic advances that have shifted the Breast cancer market scenario Visit Post
485 Down Syndrome Awareness Month Visit Post
486 ImaginAb joins hands with AstraZeneca, Pfizer, Takeda Visit Post
487 HR-positive/ HER2-negative Breast Cancer Market Insights: Upcoming Therapies and Market Analysis Visit Post
488 Global Burden of Liver cancer: Is it rising?  Visit Post
489 First oral GLP-1 treatment approved for type2 Diabetes Visit Post
490 FDA approves Bonsity for Osteoporosis treatment Visit Post
491 AngioDynamics acquires Eximo; MiroBio raises USD 33 M; Janssen submits sBLA for Stelara Visit Post
492 A New Era for Migraine Treatment and CGRP antibodies Visit Post
493 FDA is reviewing a dangerous way to treat Peanut Allergy Visit Post
494 Roche’s Tecentriq combo proves effective in Bladder cancer Visit Post
495 Batten Disease Market: Barriers and Growth Opportunities Visit Post
496 STipe raises USD 22M; FDA approves Darzalex for multiple myeloma Visit Post
497 Cystic Fibrosis Drug Market: Emerging drugs that may improve lung infections Visit Post
498 EU’s labels Nirogacestat an Orphan drug; FDA Approves First Smallpox, Monkeypox Vaccine; Evotec and Takeda collaborates to discover clinical candidates Visit Post
499 Hyperthyroidism Treatment Market and Drugs Visit Post
500 World Lung Day Visit Post
501 Flagship Pioneering launches Omega Therapeutics; EU nod to Vitrakvi; Bluebird Bio reveals positive results of Starbeam clinical trial Visit Post
502 Boehringer Ingelheim ties up with Inflammasome Therapeutics Visit Post
503 World Alzheimer’s Day Visit Post
504 Roche’s Gazyva receives FDA Breakthrough designation for Lupus nephritis Visit Post
505 Fujifilm acquires global rights to Cynata's novel therapy for GvHD; Themis raises EURO 40 million for Chikungunya vaccine; Bayer to license One Drop's digital diabetes platform Visit Post
506 FDA approves Ibsrela to reduce the global burden of Irritable Bowel Syndrome Visit Post
507 AlivaMab collaborates with Janssen for antibody discovery; Lundbeck acquires Alder BioPharmaceutical; Helsinn and Mundipharma announce China approval of Akynzeo Visit Post
508 How HR+/ HER2-Breast Cancer emerging drugs will transform the market? Visit Post
509 Global HR+/ HER2- Breast Cancer Market Scenario Visit Post
510 Genenta Sciences raises USD 14.54M; GSK announces to buy Sitari Pharmaceuticals; Mallinckrodt to Sell BioVectra for USD 25M; Lexicon to receive USD 260M from terminated diabetes partnership  Visit Post
511 Japan is transforming its Healthcare sector through Regenerative Medicine Visit Post
512 Daiichi Sankyo fuels commercialization of DS-8201 in Japan; Roivant Sciences transfers its biotech stake for USD 3 Billion; FDA, EMA accepts marketing of Allergan’s abicipar Visit Post
513 FDA approves Ofev for interstitial lung disease Visit Post
514 Metastatic HER2-Positive Breast Cancer Visit Post
515 Vertex acquires Semma; Luxturna gets approval for rare eye disorder Visit Post
516 Driving factors boosting the Hepatocellular Carcinoma Market Visit Post
517 Helsinn out licenses Pracinostat in South America Visit Post
518 Allergic Conjunctivitis Therapy Market and Pipeline Analysis Visit Post
519 How Spinal Muscular Atrophy Therapies transform market? Visit Post
520 HiFiBio raises USD 67 M; FDA drafts new guidelines for Breast cancer trials; Harbour BioMed teams up with Pharmaceutical Product Development Visit Post
521 What lies in the future for NASH upcoming drugs? Visit Post
522 Zogenix acquires Modis Therapeutics; Amgen buys Otezla; CRISPR slows down the Breast cancer rate Visit Post
523 What to expect in the Coming Years for Hairy Cell Leukemia Therapy landscape? Visit Post
524 Imfinzi fails. What’s next in Non-small cell lung cancers Market Scenario? Visit Post
525 Themis Bioscience collaborates with Merck; Oncorus raises USD 80 M; GSK files for Japanese approval of anaemia drug Visit Post
526 FDA approves Non-Controlled treatment for Excessive Daytime Sleepiness Visit Post
527 Juvenescence nets USD 100M; Sarepta DMD drug faces rejection Visit Post
528 Leber Hereditary Optic Neuropathy Treatment Market Visit Post
529 Chemotherapy-Induced Peripheral Neuropathy Market Trends Visit Post
530 EU approval for Imbruvica; Pharming licenses orphan drug Visit Post
531 Psoriasis Pipeline: Upcoming Psoriasis Treatments Visit Post
532 GNA Biosolutions raises USD 13.5M; AC Immune collaborates with Penn; Jazz Pharmaceuticals acquires Cavion; Ascletis opens a new Shanghai clinical research centre Visit Post
533 Psoriasis Therapy Market Size  Visit Post
534 Niemann–Pick disease type C Therapeutics Market Visit Post
535 NMPA approves ALS treatment Edavarone; GSK ends development of Ebola vaccines; Vesselon Acquires FDA-Approved Imagent Visit Post
536 HIV Treatment Landscape and A New Approach Visit Post
537 Turalio gets FDA approval; Sosei Heptares, Takeda forms an R&D pact Visit Post
538 DRUG-RESISTANT EPILEPSY Visit Post
539 Diabetic Gastroparesis Market Outlook Visit Post
540 FDA approval for Nubeqa; Biodesix, Immodulon collaborates on Cancer treatment; Cancer asset rights to Alligator Bioscience Visit Post
541 Frightening Surge in HIV-drug Resistance: The Biggest Challenge Ahead Visit Post
542 CHPM’s positive approval for 13 Medicines; NICE approval for AstraZeneca’s Olaparib; Exact Sciences to buy Genomic Health Visit Post
543 Global Hepatitis B Market Size Visit Post
544 World Hepatitis Day Visit Post
545 Idiopathic Pulmonary Fibrosis Market Landscape and Forecast Visit Post
546 Baqsimi wins FDA nod for Hypoglycemia; Freenome captures USD 160M; FDA approval for Ruxience for leukaemia Visit Post
547 Is it Okay to take Antibiotics without a prescription? Visit Post
548 FDA approves Lyrica; CRH Medical purchase Crystal River Anesthesia Visit Post
549 Parkinson's Disease: 5 stages, Risk Factors, Prevention, Gene Therapy Visit Post
550 Juvenile Idiopathic Arthritis Therapy Market Visit Post
551 Juvenile Idiopathic Arthritis Awareness Month Visit Post
552 PureHealth acquires LYT-100; Sosei raises USD 2.5 M Visit Post
553 Is Parainfluenza virus contagious? Visit Post
554 Recursion Pharmaceuticals nets USD 121M; Bayer's MRI agent gets a nod Visit Post
555 Juvenile Idiopathic Arthritis Etiology and Epidemiology Visit Post
556 Idiopathic Pulmonary Fibrosis –Scarring For A Lifetime Visit Post
557 Osivax raises USD 9M; Smyraf launched; Revolution secures USD 100M Visit Post
558 Myelofibrosis Therapeutics Market Visit Post
559 NICE endorsement for Pfizer’s Vizimpro; Eisai, Dundee targets Cancer; Capital raise for AgaMatrix Visit Post
560 Cutaneous T-cell lymphoma Market Outlook Visit Post
561 Generalized Pustular Psoriasis Market Visit Post
562 EU approval for Libtayo and Dovato; Boehringer expands NASH pipeline Visit Post
563 Chronic Lower Back Pain Market Analysis Visit Post
564 FDA's approval to Pfizer’s Zirabev; Launch of Century Therapeutics; Imbruvica's recommendation from CHMP Visit Post
565 Chronic Lower Back Pain Therapy Market Visit Post
566 Myasthenia gravis Market Outlook Visit Post
567 Myasthenia Gravis Awareness Month Visit Post
568 Chronic Lower Back Pain Visit Post
569 Sanifit nets USD 80.9 M; FDA approves Dupixent for CRS; AbbVie buys Allergan Visit Post
570 Post-Traumatic Stress Disorder Day Visit Post
571 EMDR Therapy- Is it really that good? Visit Post
572 Zejula's priority review; Erytech Pharma's new facility; good news for Krystal Visit Post
573 Pompe Disease Scenario in Eastern Europe Visit Post
574 Cataract Awareness Month Visit Post
575 Pompe Disease Emerging Markets Visit Post
576 Scoliosis Awareness Month Visit Post
577 Hernia Awareness Month Visit Post
578 The Business Cocktail Visit Post
579 The era of Gene therapy, and the Billion Dollar tag Visit Post
580 World Sickle Cell Day Visit Post
581 Notizia Visit Post
582 Pompe Disease Treatment Market Visit Post
583 World Blood Donor Day Visit Post
584 Pompe Disease Market Visit Post
585 Telegenomics nets $23M; Merck acquires Tilos; ADC nabs; Sobi buys Novoimmune's assets Visit Post
586 Teplizumab delays the progression of Type 1 Diabetes Visit Post
587 Notizia Visit Post
588 What is the link between Alzheimer's and Menopause? Visit Post
589 World Brain Tumor Day Visit Post
590 Lilly overtakes rivals with its Cluster Headache approval Visit Post
591 The Business Cocktail Visit Post
592 World Environment Day Visit Post
593 Antihypertensive drugs decrease Dementia rate Visit Post
594 Notizia Visit Post
595 Origins of the depressive behaviour in Huntington's disease Visit Post
596 Global Neuroendocrine Tumor Market Outlook Visit Post
597 WORLD NO TOBACCO DAY Visit Post
598 The Business Cocktail Visit Post
599 World Multiple Sclerosis Day Visit Post
600 What is causing a rise in Autism rate? Visit Post
601 Notizia Visit Post
602 Meet the World's most expensive drug: Zolgensma Visit Post
603 NASH Emerging Therapies Visit Post
604 The Business Cocktail Visit Post
605 Off-label therapies dominate NASH Market Share Visit Post
606 Notizia Visit Post
607 Beware! Season of Lyme has come Visit Post
608 Pulmonary Arterial Hypertension Therapies Visit Post
609 World Hypertension day Visit Post
610 Ginkgo to buy mining platform; Vertex, Kymera collaborate; ArcherDX nets $60M; Bayer to invest $150M Visit Post
611 Antitrypsin Deficiency Pipeline Visit Post
612 Notizia Visit Post
613 Unmet Needs in the treatment of Antitrypsin deficiency Visit Post
614 Acne Vulgaris Market Outlook Visit Post
615 AstraZeneca-Daiichi’s results; Novartis remunerates; Pfizer to acquire Therachon; Gilead & Goldfinch Bio collaboration Visit Post
616 Acute Bacterial Skin and Skin Structure Infections Emerging Therapies Visit Post
617 World Thalassemia Day Visit Post
618 World Ovarian Cancer Day | 2019 Visit Post
619 Notizia Visit Post
620 ABSSSI Current Therapeutic Market Visit Post
621 Spinal Muscular Atrophy Market Visit Post
622 Ovarian Cancer Treatment Drugs and Unmet Needs Visit Post
623 The Business Cocktail Visit Post
624 European Commission gives a nod to Zynquista for type 1 diabetes in adults Visit Post
625 Notizia Visit Post
626 Spinal Muscular Atrophy: Current and Emerging Therapies Visit Post
627 Parkinson's Awareness Month 2019 Visit Post
628 Recent Market Reports Visit Post
629 Spinal Muscular Atrophy Market is expected to augment at a CAGR of 10.42% Visit Post
630 Autism Spectrum Disorder Visit Post
631 GSK to spend $100M; Lilly sell; Sherlock Bio raises $31M; Deerfield, UIC to foster research Visit Post
632 World Malaria Day Visit Post
633 World Immunization Week Visit Post
634 Can Spinal Muscular Atrophy be treated by Protease Inhibitors? Visit Post
635 Notizia Visit Post
636 Global Parkinson’s Therapeutic Market Outlook Visit Post
637 Can commoners afford to spend million dollars on GENE Therapy? Visit Post
638 Amgen reveals price; Bardy raises $35.5M; Kiadis to Acquire CytoSen; Insitro lands a deal Visit Post
639 World Haemophilia Day Visit Post
640 Beta Interferons prolongs life in Multiple Sclerosis Visit Post
641 Notizia Visit Post
642 New Osteoporosis Drug promises to rebuild Bone Visit Post
643 Gene Therapy in Oncology: Innovation to Commercialization Visit Post
644 Inozyme Raises $67M; Shanghai Miracogen partners with Synaffix; EdiGENE raises $15M; Antengene announces its expansion Visit Post
645 The promising Pipeline for Gene Therapy In Oncology Visit Post
646 Notizia Visit Post
647 World Health Day Visit Post
648 Current and Emerging therapies that change Traveler’s Diarrhea Market Visit Post
649 AgomAb Therapeutics raises $23.5M; Allergan's eye drug; Good news for the patients; Dyne Therapeutics comes to life Visit Post
650 What can be the scope of Medical Marijuana? Visit Post
651 Notizia Visit Post
652 Boys are more likely to have autism! Visit Post
653 Global Traveler's Diarrhea Market Visit Post
654 Multiple Myeloma Day Visit Post
655 The Business Cocktail Visit Post
656 Alzheimer's drug fails! Is it time to move on? Visit Post
657 World Epilepsy Day Visit Post
658 Notizia Visit Post
659 EPILEPSY- A Neurological Disorder Visit Post
660 World Tuberculosis Day Visit Post
661 Complex regional pain syndrome (CRPS)-A debilitating disease Visit Post
662 The Business Cocktail Visit Post
663 Japan has got new ways to treat corneas Visit Post
664 World Oral Health Day Visit Post
665 Approach for Cystic Fibrosis; An alternative for Statins; Oral medications not safe; Carbon monoxide poisoning treatment gets approval Visit Post
666 Narcolepsy now a confirmed Autoimmune Disorder Visit Post
667 The changing landscape of Multiple Myeloma therapies market Visit Post
668 World Glaucoma Week Visit Post
669 BioNTech lines up $800M; Deerfield remunerates; Britain's Smith & Nephew to acquire Osiris Visit Post
670 World Kidney Day Visit Post
671 Welcome the Slumber Visit Post
672 NO SMOKING DAY Visit Post
673 Notizia Visit Post
674 Where Women Healthcare Stands Visit Post
675 Wearing Technology to stay fit Visit Post
676 Biogen buys Nightstar; Pacira acquires Myoscience; Horizon Pharma announces pricing; STAT with Slingshot Insights; Epizyme announces Equity Offering Visit Post
677 FDA just lost a gem as Scott Gottlieb resigns Visit Post
678 ColdZyme inactivates viruses; Med for rare genetic disease; Common oral bacteria accelerate Colon cancer; CEPI and CureVac to develop an mRNA vaccine; Celastrol’s effectiveness Visit Post
679 Cost ineffective Orphan Drugs limit the access Visit Post
680 Rare Disease Day Visit Post
681 The Business Cocktail Visit Post
682 A helping hand in treatment of CRC Visit Post
683 Notizia Visit Post
684 A CRISPR WAY TO USE STEM CELLS Visit Post
685 What is Cholangiocarcinoma (CCA)? Visit Post
686 Peloton raises $150M; BiomX raises $32M; Abbott and Novo collaborate; Blaze Bioscience nets $5M Visit Post
687 CRISPR proves to be a blessing for LASSA fever Visit Post
688 Notizia Visit Post
689 Human cells reprogrammed to create insulin in diabetic mice Visit Post
690 Neurogene raises $68.5M; AbbVie and Teneobio sign deal; 5AM Ventures nets Visit Post
691 The antidepressant drug gets support from FDA Visit Post
692 Antidepressant of J&J leads to FDA; SCLC model discloses; Genes and macular degeneration can disclose new treatment ways Visit Post
693 Raynaud's Disease -A debilitating condition Visit Post
694 Acromegaly Visit Post
695 Genentech remunerates Xencor; XPrize upraises fund; GSK gambles Visit Post
696 Relation between gut microbes and depression bolstered Visit Post
697 Notizia Visit Post
698 Myasthenia Gravis Visit Post
699 Neuroendocrine Tumors (NETs) Visit Post
700 Voyager clears Neurocrine deal; Anthem speeds up launch; Lilly rushed its deal Visit Post
701 Biodesix collaborates with MRM; Avoiding flu with an antibody; Soliris clears trial Visit Post
702 Molecular Profiling Could Help in Early Lung Cancer Detection: Study Visit Post
703 BridgeBio bags $299M; Immunochina receives $20M; Attune raises; Wren receives $23M Visit Post
704 ‘Software’ differences between humans and monkeys Visit Post
705 Notizia Visit Post
706 Cervical cancer Visit Post
707 Virtual Reality Maps Helps Doctors Understand Cancer Tumor Structure Visit Post
708 Juvenescence raises $46M; Brainsway files for IPO; Life Biosciences raises Visit Post
709 Highly mutated cancers respond better to immune therapy Visit Post
710 Notizia Visit Post
711 Triple Negative Breast Cancer Responds to TINAGL Therapy Visit Post
712 Apollomics raises; Pear Therapeutics raises $64M; Lilly to acquire Loxo Visit Post
713 Artificial Intelligence face-scanning app spots signs of rare genetic disorders Visit Post
714 Sage’s drug meets phase 3; Blocking 2 key pathways help in tackling TNBC; FDA clears Paragonix; FDA gives a nod Visit Post
715 Machine Learning Models to Help Predicting Cancer Symptoms, Plan Treatment Visit Post
716 Atlas Venture raises; Harpoon files IPO; Boston Scientific bags Millipede Visit Post
717 Where in the world could the first CRISPR baby be born? Visit Post
718 Cervical cancer: What you need to know Visit Post
719 Vedanta raises; Relay Therapeutics reels in; Gene therapy for SMA Visit Post
720 ‘Transmissible’ Alzheimer’s theory gains traction Visit Post
721 Tetra, Shionogi sign deal; Amgen remunerates; Gilead’s fibrotic disease deal Visit Post
722 Attention-Deficit/Hyperactivity Disorder (ADHD) Visit Post
723 How Neanderthal DNA might have shaped some human brains Visit Post
724 HER2 Drug Meets Phase 1b; Neurons ward off Alzheimer’s; Bristol-Myers, H3 Biomedicine discover RNA splicing Visit Post
725 66 Year Ohio Woman Becomes Cancer Free, Thanks to CAR T Cell Therapy Visit Post
726 Now, Artificial Intelligence to Accurately Identify Cancer Cells Visit Post
727 Lilly remunerates AC Immune; Akero adds $70M; Ra Pharma $100M Visit Post
728 Baby gene edits could affect a range of traits Visit Post
729 Notizia Visit Post
730 Gold Nanoparticles May Soon Treat Prostate Cancer Visit Post
731 Cancer Cells Trick Body’s Immunity to Survive against Treatment Visit Post
732 Roche signs Icagen; UCB devote $255M; Siemens Healthineers celebrates Visit Post
733 Breakthrough Device Designation granted to the AI Software for CTEPH Visit Post
734 Does coconut oil help prevent dementia? Visit Post
735 Notizia Visit Post
736 WORLD AIDS DAY - 2018 Visit Post
737 Scientists Now Target Attacking Evolution Process of Cancer Cells Visit Post
738 Prometic bags $50M; Vedanta receives $12M; Humira biosimilar deal Visit Post
739 Researchers say CRISPR edits to a human embryo worked Visit Post
740 Sleeping at Workplaces: Re-energizing Formula or OSA Disease? Visit Post
741 Chemotherapy as a treatment for Cancer?  Visit Post
742 Cambrex acquires Avista; Sobi pays $50M; LEO Pharma signs deal; Boston Scientific remunerates Visit Post
743 Newsletter Visit Post
744 The lab-grown mini-brains generate electrical patterns Visit Post
745 Notizia Visit Post
746 Actinic Keratosis – A Warning Sign for Potential Skin Cancer Visit Post
747 WORLD CHRONIC OBSTRUCTIVE PULMONARY DISEASE DAY Visit Post
748 Synthorx needs IPO; Deerfield puts up $80M; SVB remunerates; Celgene’s deal Visit Post
749 ‘Invisible’ mice reveal anatomical secrets Visit Post
750 World Diabetes Day | 2018 Visit Post
751 World Diabetes Day Visit Post
752 Notizia Visit Post
753 Virus, the Cancer Therapy of the Future Visit Post
754 Triple Negative Breast Cancer Visit Post
755 Gordon and Betty Moore Foundation gives $85M; Omeicos raises; Sanofi signs deal; Lilly grabs Visit Post
756 Cholera vaccine delivered; Rice-inspired breakthroughs; International partnerships Visit Post
757 FDA approves Zulresso; Pfizer receives approval; Novartis relinquishes Rituxan Visit Post
758 Lung Cancer Infographic Visit Post
759 150 Year Old Drug Indicates Potential of Future Cancer Therapy Visit Post
760 Calciphylaxis: Rare Yet Potentially Fatal Visit Post
761 Gilead remunerates; Roche taps Halozyme’s drug delivery tech; Orchard Therapeutics prices its IPO Visit Post
762 The risk of solid cancer after chemotherapy Visit Post
763 Notizia Visit Post
764 Meeting the Unmet Need for Oral Mucositis Visit Post
765 Innovent Biologics reaps; Jeff Aronin’s lead; Alexion gives out; Stoke Therapeutics receives Visit Post
766 Notizia Visit Post
767 INSIGHTS ON TRIPLE NEGATIVE BREAST CANCER Visit Post
768 Novartis signs; Sosei passes; Amgen remunerates; J&J remunerates for RSV drug Visit Post
769 Drugmakers will now have to reveal medicine prices in television ads Visit Post
770 Notizia Visit Post
771 Is Gene Therapy the Next Cancer Treatment Revolution?  Visit Post
772 COMMERCIAL AND OTHERS Visit Post
773 KEY CLINICAL OUTCOMES Visit Post
774 Copiktra receives approval; Lilly wins approval; Eisai’s Fycompa; Astellas’ Roxadustat; Janssen’s Esketamine Nasal Spray Visit Post
775 Orchard files for IPO; J&J puts money on RNA interference; Rgenix receives $40M; GSK gives a helping hand Visit Post
776 The novel therapy for brain cancer treatments Visit Post
777 Notizia Visit Post
778 Precautions for Breast Cancer Visit Post
779 Hologic complements Focal; Allogene for IPO; Gamida, Novartis-backed cell therapy startup; Aduro loses partner Visit Post
780 Antidepressants withdrawal hits millions of people Visit Post
781 BREAST CANCER AWARENESS MONTH Visit Post
782 WORLD HEART DAY | 29-09-2018 Visit Post
783 Companion Diagnostics Visit Post
784 Ceribell raises $35M; Lyra reels $29.5M; Minoryx raises Euro21M; Alexion acquired Syntimmune Visit Post
785 Can GABA turn pancreatic α-cells into β-cells? Visit Post
786 Notizia Visit Post
787 Researchers Turn towards Light to Solve Lung Cancer Puzzle Visit Post
788 Epic Sciences garners; Tvardi gets financing; Galera raises; Fund for cancer research Visit Post
789 Snippet Visit Post
790 Biologic Parallel – A Perky Future Ahead Visit Post
791 Notizia Visit Post
792 Pancreatic Cancer Treatment to Stride Beyond Chemotherapy Visit Post
793 Atreca secured $125M; OncoResponse bags $40M; Kodiak Sciences’s IPO; Biodesy contemplates $20M Visit Post
794 Snippet Visit Post
795 Notizia Visit Post
796 Neuroendocrine tumors (NETs): The complex group of tumors Visit Post
797 Now, Nanoparticles for Cancer Treatment Visit Post
798 4D Molecular Therapeutics raises; Arvinas slates for IPO; Sutro ruminates for $ 75M; Emergent BioSolutions remunerates Narcan maker Visit Post
799 SNIPPET Visit Post
800 Notizia Visit Post
801 Orphan Drug Act and Its Criticism Visit Post
802 Commercial Visit Post
803 Clinical Visit Post
804 AbbVie Receives Approval; Kymriah Approved; Shire Gets USFDA Approval; NICE Rejects; Bristol-Myers Squibb’s Opdivo; Eisai and Merck Get USFDA Approval Visit Post
805 Outset Medical captures; Wright Medical Group to takeover Cartiva; Y-mAbs Therapeutics prepares for IPO; Biotech boom remunerates analysts Visit Post
806 Snippet Visit Post
807 Notizia Visit Post
808 China Preparing for Pharma Big Bang: Is this Alarm Bell for US, Euro Pharma Giants? Visit Post
809 Japan Manages to Stand Apart from Global Hepato Cellular Carcinoma Crowd Visit Post
810 AZ dragout Entasis; Sierra remunerates Gilead; Principia raises; Harbour BioMed and Kelun pen deal Visit Post
811 Snippet Visit Post
812 Kalydeco got approved; Opdivo for SCLC; FDA approved for pain relief; GC4419 obviates Visit Post
813 Idiopathic Pulmonary Fibrosis (IPF) – When to start and what is coming in the race to treat the deadlier constricts…. Visit Post
814 Voltage-Dependent T-Type Calcium Channel Blockers  Visit Post
815 KEY CLINICAL OUTCOMES Visit Post
816 Regulatory Visit Post
817 Commercial Visit Post
818 The Business Cocktail(Therapeutics) Visit Post
819 Personalized Medicine Approach: An Upholding Paradigm for a Promising and futuristic Patient Centric Health Care Visit Post
820 Sarepta’s deal; Fund raisings for Apexigen; Novo funded rare disease startup Visit Post
821 Snippet : Genetic Mutation Visit Post
822 Snippet : Migraine Visit Post
823 Progenics got FDA Approval; Curcumin to cancer cells Visit Post
824 Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) – a lesser developed window Visit Post
825 Sutro nets $85.4M; HiFiBiO pens Takeda R&D collaboration Visit Post
826 Snippets : Parkinson Visit Post
827 Niemann-Pick disease type C (NPC) -A Rare Cognitive Decline Indication Visit Post
828 Snippet : Endometriosis Visit Post
829 Snippet : Acute lymphoblastic leukemia Visit Post
830 Business Cocktail Visit Post
831 Commercial Outcomes - Novartis Visit Post
832 Key Clinical Outcomes- 30/07/2018 Visit Post
833 Neuroscience Highlights - 17/07/2018 Visit Post
834 Oncology Highlights - 30/07/2018 Visit Post
835 Predicting risk of Acute Myeloid Leukemia (AML) in healthy individuals Visit Post
836 Notizia Visit Post
837 Allergic Conjunctivitis (AC)- Market Insights, Epidemiology and Market Forecast- 2027 Visit Post
838 Allergic Conjunctivitis (AC) – Common disorder with increasing prevalence Visit Post
839 Fatty Acid Amide Hydrolase (FAAH) Inhibitor – an enzyme with novel therapeutic potential Visit Post
840 Hepatic Encephalopathy- An ailment of liver to brain Visit Post
841 NF-κB Inhibitors- A Promising Future Visit Post
842 Idera's drug; CRISPR increase risk; Juvenescence grabbed USD 50M; AstraZeneca, Lilly terminates Visit Post
843 Axovant rely on gene therapy; CAR-T treatments; Pfizer’s dacomitinib; Adaptimmune construct manifestation Visit Post
844 Parkinson's and tuberculosis shares a common protein that could provide better drugs for both Visit Post
845 Celiac vaccine trial; New discovery in Nicotine; Nabriva lines up FDA filing; Rare Disease drug development accelerating Visit Post
846 Business Cocktail Visit Post
847 Potential cure for Common cold Visit Post
848 Hematopoietic Stem Cell Transplantation Visit Post
849 Takeda buys Shire in a deal worth USD 62 billion Visit Post
850 Atara Biotherapeutics hires; Minor effects of multiple genes determine migraine risk; Celgene set to refile ozanimod Visit Post
851 Horizon Discovery declines Abcam’s USD 367 million takeover bid Visit Post
852 Notizia Visit Post
853 Phase 1 data of CYC065; Lysogene delays phase 3 study; Genetic disorders Diagnosis; PD-1 resistance in melanoma patients Visit Post
854 STAT INHIBITORS- Highly active Pipeline Visit Post
855 Chronic Inflammatory Demyelinating Polyneuropathy – lack of Effective treatment Visit Post
856 Cellectis successfully bags USD 164 million for Gene-editing and CAR-T programs Visit Post
857 Hepatic Encephalopathy- Lack of active pipeline products Visit Post
858 Takeda acquisition on Shire raises its share by 25 percent Visit Post
859 Business Cocktail Visit Post
860 Business Cocktail Visit Post
861 New method for classification of CNS tumors Visit Post
862 Notizia Visit Post
863 Hyperuricemia – Uric acid disorder, a gateway to other diseases Visit Post
864 Business Cocktail Visit Post
865 Cholesterol drug Praluent successful in reducing heart risk Visit Post
866 Notizia Visit Post
867 Celiac Disease – Intestinal damage of Gluten Visit Post
868 Transthyretin Amyloidosis (ATTR) Competitive Landscape, Market Insights, Epidemiology and Market Visit Post
869 NOTIZIA Visit Post
870 Nonalcoholic Steatohepatitis (NASH): Highly Epidemic Visit Post
871 Meeting the Unmet: Nonalcoholic Steatohepatitis (NASH) Visit Post
872 Snippet: M&A activities of big pharma’s will fuel CAR-T cell therapy Visit Post
873 The Business Cocktail : Latest Pharma deals Visit Post
874 CRISPR to cure sickle cell; FDA rejected; Stem cells use; Celgene spinoff Visit Post
875 Immune Checkpoint Activators (ICA): Dynamic Therapeutic Targets Visit Post
876 Symdeko’s approval; Erytech target solid tumors; Oncologie snapped bavituximab; Merck delivers Visit Post
877 Gilead Sciences  launched a highly effective hepatitis C drug Sovaldi Visit Post
878 Business Cocktail Visit Post
879 Natural Killer Cell Therapies: An Emerging Cellular Therapy Visit Post
880 Involvement of B cells in the pathogenesis of primary Sjögren syndrome (pSS) Visit Post
881 Notizia Visit Post
882 Spasticity Visit Post
883 Business Cocktail Visit Post
884 In vivo monitoring of T cell–dendritic cell interactions by intercellular enzymatic labelling Visit Post
885 Notizia Visit Post
886 Familial Amyloid Polyneuropathy – An uncommon medical condition Visit Post
887 Pandion bags $58M; Carmot Therapeutics grabs $15M; Innovent looks for IPO; Collaboration of Sandoz & Biocon Visit Post
888 Notizia Visit Post
889 Retinal Degeneration : The Current Pipeline Scenario Visit Post
890 Adapsyn signed; Evolus filed; BioNTech signed a deal; Nordisk’s deal Visit Post
891 Snippet Visit Post
892 Notizia Visit Post
893 Hereditary Angioedema (HAE) – Active drug pipeline Visit Post
894 Business Cocktail Visit Post
895 Snippet Visit Post
896 NOTIZIA Visit Post
897 Regeneron/Sanofi’s PD-1 drug candidate; Zika targeting drugs and vaccines developments; CMO of Achillion will leave this month; Lincoln's anti-malarial drug Visit Post
898 Systemic Lupus Erythematosus (SLE) – Market Is Expected to Grow with Upcoming Therapies Visit Post
899 Roche’s Phase 2 data; Celgene and Bluebird’s CAR-T therapy; Regeneron/Sanofi gets results; Allergan on women’s health Visit Post
900 Gaucher Disease: “Rare Disorder with High Unmet Needs” Visit Post
901 December 7 Business Cocktail Visit Post
902 KINECT 4 Study; KindredBio Announces Results; Mylan and Aspen’s Launch; EMA investigates; Amgen’s Repatha Visit Post
903 Toll-Like Receptor Modulators: Emerging therapy for many indications Visit Post
904 Ketamine to work in mice Visit Post
905 Biohaven’s trial ; GSK integrates; FDA Approval; Phase III trial Visit Post
906 Celiac Disease (CD) – Upcoming therapies to break the stagnancy Visit Post
907 Targeting cancer through CD40 agonists -A promising future Visit Post
908 EMA to relocate to Amsterdam; Roche’s prospects; Amgen’s Humira Biosimilar delayed; Purdue’s opioid lawsuit Visit Post
909 Chemists may help solve the air-pollution health crisis Visit Post
910 Novartis ventures; Bill Gates invests; Arcus Biosciences gains; Denali and Odonate seek funding; Fosun Pharma acquires Visit Post
911 Bubble Boy Syndrome (ADA-SCID) - A Rare Immunodeficiency Disorder Visit Post
912 Business Cocktail Visit Post
913 'Killer' Mosquito to be released in 20 US states to fight mosquitoes Visit Post
914 Teva sells generics; Valeant trades; Roche's Genentech; J&J's next potential frontier Visit Post
915 Wiskott - Aldrich syndrome – a rare X-linked disorder Visit Post
916 AstraZeneca and Incyte Collaborate; Tocagen’s therapy; FDA warns companies;FDA Revokes Visit Post
917 Metachromatic Leukodystrophy (MLD): A Rare Indication with great unmet medical need Visit Post
918 Wet AMD: A chronic eye condition with promising therapies Visit Post
919 Publishers collaborate to remove journal articles from ResearchGate Visit Post
920 Novo petitions FDA;J&J invests; Xarelto’s trial; Roche's Tecentriq Visit Post
921 Natural Killer Cell Therapies– Advancing technology increasing competition among the companies Visit Post
922 C-X-C Chemokine Receptor Inhibitors–The Emerging Therapeutic Agents Visit Post
923 Therapeutics and Celgene to develop therapies; Takeda’s expansion; J&J hopes to limit; Tech Prize for genome sequencing; Endocyte’s late-stage prostate cancer deal Visit Post
924 Alzeimer’s drug; Guardant Health receives approval; First Patient Dosed in Phase 1 Clinical Trial; Sunny Pharmtech and Vitruvias Therapeutics Receive FDA Approval Visit Post
925 Isocitrate dehydrogenase (IDH) inhibitors– Emerging Anti-Cancer Therapeutics Visit Post
926 Thrombolytic Sciences’ trial; NurOwn for ALS; Biosimilar receives approval; Trelegy Ellipta for the treatment of COPD Visit Post
927 Oral Mucositis – A Common Cancer Therapy Adverse Reaction Visit Post
928 Human Papillomavirus (HPV) Prophylaxis– Expected to see a steady growth from 2015-2025 Visit Post
929 Business cocktail Visit Post
930 South Korean researchers influencing lift of human-embryo restrictions Visit Post
931 Idera’s Phase I Data; DelMar Initiates Trial; Novartis’ study; Humira gets EC approval Visit Post
932 HDAC (Histone Deacetylase) Inhibitors – A Promising Anti-Cancer Target Visit Post
933 Amyotrophic Lateral Sclerosis (ALS) a fatal disease! Visit Post
934 CAR-T Phase I trials; ContraVir Announces; Merck acquired; Excision BioTherapeutics bags $10M Visit Post
935 Cancer Globally (Vol. 1, Issue 1) Visit Post
936 Reprogrammed cells relieve Parkinson's symptoms in trials Visit Post
937 Bruton's Tyrosine Kinase (BTK) Inhibitors An Emerging Therapeutic Target Visit Post
938 Can-Fite Receives Payment; Leafbuyer Technologies and Denver Post’s Cannabist; EPX-300 & JOTROL received Designation; New treatment Approved for adults Visit Post
939 Social Behavior Loss Observed in Gene-edited ants through CRISPR Visit Post
940 PARP Inhibitors making inroads into Ovarian Cancer Visit Post
941 Friedrich's ataxia: Rare disease Visit Post
942 Business CockTail Visit Post
943 Natural Killer Cell Therapies– Advancing technology increasing competition among the companies Visit Post
944 Bristol-Myers Squibb to nix; Pfizer commits $100M; Merck and GSK production issues; Shire unloads plant Visit Post
945 Genetically Engineered Salmon : Are you up for dinner? Visit Post
946 Cannabidiol trial; MyoKardia aims; LDL drug data Visit Post
947 CDK 4/6 Inhibitors- The Changing Paradigm for Breast Cancer Treatment Visit Post
948 Allergan sell; AZ, Merck team up; Roche’s MS drug; Chinese API maker receives a warning letter Visit Post
949 Innovate the UK, aiming to drive efforts to commercialize research Visit Post
950 Remicade’s launch; Endo cuts jobs; Analysts downgrade Pfizer; Corning $500M glass project Visit Post
951 Interstitial Cystitis : Promising Scope for Research Visit Post
952 Takeda scores; PhRMA launches; Valeant's Obagi; Ex-Novo executive signs Visit Post
953 Georgia physician to lead US public-health agency Visit Post
954 Gilead faces lawsuit; Herceptin stalled; Lilly revs up, Abemaciclib gets nod; Key Humira patent gets struck down Visit Post
955 Stada’s €5.3B; Pfizer takes 30 cents; GSK, Exscientia ink deal; Trillium hunts for partners; Clementia files for $115M IPO Visit Post
956 Actinic Keratosis – A Warning Sign for Potential Skin Cancer Visit Post
957 Merck got attack; Stada's €5.32B; Private equity fund buys; Lonza on $5.5B deal Visit Post
958 Elsevier Granted millions in damages from Sci-Hub by US Court Visit Post
959 Takeda knocks Velcade; FDA nod awaited; Novartis gets approval; Astellas UK dodges; Haegarda set for launch Visit Post
960 Novartis on AMD drug; Hospira recall of vials; Takeda wraps up; FDA bans imports Visit Post
961 China cracks down on fake peer reviews Visit Post
962 J&J nabs; Clovis plots Rubraca; Novartis scores EU approval; Seattle Genetics stops trials Visit Post
963 Urinary Tract Infections (UTIs)– How is it affecting the Globe? Visit Post
964 Sanofi invests; ICER pitches; $6M in NIH; Pfizer, Roche cancer drug pricing Visit Post
965 New cancer drug tested in mice may benefit certain leukaemia patients Visit Post
966 Invokana matches; Xultophy beats; Lilly and BI follow; Tresiba matches Visit Post
967 AZ offloads; Pfizer's deal; Takeda’s work on plant; Germany's doc payment Visit Post
968 Gut bacteria can stop cancer drugs from working Visit Post
969 Dendreon touts; Zytiga slashes risk; Lynparza posts; Dacomitinib wins; Alecensa trounces Visit Post
970 Tesaro’s Zejula; Mylan on EpiPen; Ohio sues drugmakers; ATUM, Horizon Discovery Announce deal Visit Post
971 Bio-manufacturing with Spider Silk for pre-term babies Visit Post
972 Roche, Boehringer tout; Pfizer, Bristol-Myers got sued; FDA commissioner unveils; EpicGenetics expands Visit Post
973 Vitiligo – High Unmet Need Indeed! Visit Post
974 Progressive Supranuclear Palsy– A neurodegenerative disorder Visit Post
975 Merck's Remicade; Sanofi, Regeneron set Kevzara; Novartis to sever; Teva puts women's health Visit Post
976 FDA grants accelerated approval to pembrolizumab Visit Post
977 AZ’s benralizumab; Sanofi, Regeneron set; Nordisk preps; European countries offer Visit Post
978 Humira’s patent; Teva laying off; GSK aims; Thermo acquires Patheon; J& J's Invokana Visit Post
979 Geneticists enlist engineered virus & CRISPR to battle citrus disease Visit Post
980 Novartis, slammed by Korean scandal; FDA tweaks; Dendreon eyes; Amgen adds Visit Post
981 Cutaneous Squamous Cell Carcinoma Market & pipeline Visit Post
982 Valeant's $50M; Sanofi vows; Top pharmas team up; PhRMA expels Visit Post
983 Scientists relieved by Emmanuel Macron’s French election victory Visit Post
984 Lilly moves ahead; Authorities raid; Bristol-Myers, AZ in legal; PhRMA expected to weed out Visit Post
985 World Ovarian Cancer Day Visit Post
986 Insight on Interstitial Cystitis- The Bladder Pain Syndrome Visit Post
987 Merck’s Keytruda sales; Valeant on name change; Pfizer – BMS; Amgen puts Repatha outcomes for deal Visit Post
988 Science wins reprieve in US budget deal Visit Post
989 FDA Approves; AZ nabs; Nordisk settles; Novartis pays Visit Post
990 Hemophilia: A Lifelong Genetic Disorder Visit Post
991 Urinary Incontinence: Epidemiology Insight on Leaking Bladder Visit Post
992 Merck sells biosimilars; AbbVie’s PARP; Pharma heads; Biogen looks to M&A Visit Post
993 Cord Blood makes brains of elderly mice young again Visit Post
994 Samsung biosim nod sets; Lilly's med hits; BioMarin sees pricing; Spinraza scores; Klick creates Visit Post
995 Non-Hodgkin Lymphoma: “Malignant Growth of White Blood Cells” Visit Post
996 Chemotherapy-Induced Nausea and Vomiting Side effects Visit Post
997 Drug shortage; Fujifilm invests; Cobra Biologics to pump $19M; The world's most pricey drugs Visit Post
998 The Snippet: Targeting metabolism in Renal Cell Carcinoma Visit Post
999 Novartis gets CAR-T drug; Shire aims to block; Xeljanz stands; Payer snubs; Lawmakers pass a bill Visit Post
1000 Whitepaper: Impact of Brexit on Pharma Space Visit Post